Elafibranor Patent Expiration
Elafibranor was first introduced by Ipsen Biopharmaceuticals Inc
Elafibranor Patents
Given below is the list of patents protecting Elafibranor, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Iqirvo | US12673035 | Solid Dosage Forms Of Elafibranor | Mar 05, 2044 | Ipsen |
| Iqirvo | US11185519 | Methods of treatment of cholestatic diseases | Mar 30, 2037 | Ipsen |
| Iqirvo | US11331292 | Methods of treatment of cholestatic diseases | Mar 30, 2037 | Ipsen |
| Iqirvo | US11850223 | Methods of treatment of cholestatic diseases | Mar 30, 2037 | Ipsen |
| Iqirvo | US11857523 | Methods of treatment of cholestatic diseases | Mar 30, 2037 | Ipsen |
| Iqirvo | US12233038 | Methods of treatment of cholestatic diseases | Mar 30, 2037 | Ipsen |
| Iqirvo | US12295927 | Methods of treatment of cholestatic diseases | Mar 30, 2037 | Ipsen |
| Iqirvo | US12295928 | Methods of treatment of cholestatic diseases | Mar 30, 2037 | Ipsen |
| Iqirvo | US12310935 | Methods of treatment of cholestatic diseases | Mar 30, 2037 | Ipsen |
| Iqirvo | US12589086 | Compositions And Methods For The Treatment Of Primary Biliary Cholangitis | Mar 30, 2037 | Ipsen |
| Iqirvo | US7632870 | Composition based on substituted 1,3-diphenylprop-2-en-1-one derivatives, preparation and uses thereof |
Sep 09, 2024
(Expired) | Ipsen |
| Iqirvo | US7943661 | Substituted 1,3-diphenylprop-2-en-1-one derivatives and preparation and uses thereof |
Sep 09, 2024
(Expired) | Ipsen |
Elafibranor's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Elafibranor:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| A Study to Assess Safety and Effectiveness of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis. | Ipsen | NA |
ACTIVE NOT RECRUITING
(Aug 1, 2026)
| PHASE2 |
| A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis | Ipsen | NA |
RECRUITING
(Aug 1, 2026)
| PHASE3 |
| A Study of Elafibranor in Adult Japanese Participants With Primary Biliary Cholangitis (PBC) | Ipsen | NA |
ACTIVE NOT RECRUITING
(Aug 1, 2026)
| PHASE3 |
| A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis | Ipsen | NA |
RECRUITING
(Aug 1, 2026)
| PHASE3 |